Brian Orelli Articles

•   RSS Feed
• View Profile

Last 50 articles...

• Pick Your Poison: Overweight or High Cholesterol
• Cancer Meeting Highlights the Good and Bad of the Immune System
• Weight Loss Isn't Just for Looking Good Anymore
• Racing Toward the Next Hepatitis C Drug Approval
• Diversifying Royalties at a Hefty Cost
• Some Fish Oil Doesn't Help Some Patients in Some Countries
• The First Step in Treating Type 2 Diabetes
• No Fat in This Drug Launch
• This Biotech Is Looking for a Fourth-Quarter Comeback
• Obesity Drug Demand Still Low
• The Long Wait for This Obesity Drug Is Almost Over
• Looking For Real Viagra? Head to the Internet.
• U.S.-Approved Obesity Drug Derailed in EU
• FDA Approves Powerful New Cholesterol Drug
• Shorter Treatments for Hepatitis C Patients on Their Way
• Merck Stock Down, Could Have Been Worse
• An Animal of a Quarter
• 3 Investment Ideas for Biotech Investors
• Take 2 Dividend Stocks and Call Me in the Morning
• Abbott Laboratories Stock Is Half What It Used to Be
• Investing in Biotech Companies? Know These Names!
• How Will Merck Stock Do After Earnings?
• What News Will Drive Amgen Stock Next?
• 3 Biotech Companies Ripe for a Takeover
• Pfizer Stock Is All Grown Up
• A New Diabetes Duo Emerges
• Biotech Companies Breaking Up
• Hepatitis C Drugmakers Hook Up to Develop Cocktail
• A Cystic Fibrosis Backup Plan
• FDA Says, "Call Me Maybe"
• These Biotech Investors Are Far From Depressed
• Powerful Cholesterol-Lowering Drugs on Their Way
• 3 Ways Your Pet Can Make You a Better Investor
• Johnson & Johnson Stock Is on the Mend
• FDA Makes Obesity Drug Available to More Americans
• Royalty Pharma Willing to Pay More for Elan, Depending on Investor Demands
• The FDA Helps Investors Breathe Well
• Obama's Budget Hurts Seniors, Helps Hospitals
• More Than an Obesity Drug Company
• FDA Throws ACADIA a Juicy Bone
• Oral Hepatitis C Cure on Its Way
• FDA's Breakthrough Therapy Designation More Bling Than Bite
• Understanding Why Cancer Vaccines Fail
• 3 Reasons Buffett Hates Biotech
• Get Paid to Lose Weight
• This Pharma's Dividend Is Safe for Now
• Up 76% Overnight With Room to Run
• 3 Reasons Investors Are Scared of Biotech Stocks
• How's That Long-Term Biotech Investment Looking?
• A Silver Lining in a Sea of Red